NEW YORK, June 22, 2017 /PRNewswire/ --
If you want a Stock Review on MDXG, SYK, ZBH or RMD then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. Today's research on DailyStockTracker.com is dedicated to these four equities: MiMedx Group Inc. (NASDAQ: MDXG), Stryker Corp. (NYSE: SYK), Zimmer Biomet Holdings Inc. (NYSE: ZBH), and ResMed Inc. (NYSE: RMD). The Medical Appliances and Equipment industry primarily offers equipment and devices, which are designed for diagnosis, monitoring, and treatment of patients in healthcare systems. These free stocks reports are currently available on DailyStockTracker.com. Simply sign up for your complimentary member access at:
Marietta, Georgia headquartered MiMedx Group Inc.'s stock finished Wednesday's session 4.06% higher at $15.63. A total volume of 2.02 million shares was traded, which was above their three months average volume of 1.55 million shares. Over the last month and the previous three months, the Company's shares have advanced 9.07% and 76.41%, respectively. Additionally, the stock has gained 76.41% since the start of this year. Shares of the Company are trading above their 50-day and 200-day moving averages by 16.59% and 57.90%, respectively. Moreover, shares of MiMedx, which develops, processes, and markets patent protected and proprietary regenerative biomaterial products and bio-implants processed from human placental tissue, skin, and bone, have a Relative Strength Index (RSI) of 67.65.
On May 23rd, 2017, research firm First Analysis Sec downgraded the Company's stock rating from 'Equal-Weight' to 'Underweight'.
On June 15th, 2017, MiMedx announced that the latest, peer-reviewed, scientific and clinical review article of the Company's dehydrated human amnion/chorion membrane allografts has been electronically published in the journal Techniques in Orthopaedics. The paper, titled "Dehydrated Human Amnion/Chorion Membrane Allografts as a Therapy for Orthopedic Tissue Repair," was authored by Jennifer Lei, PhD; Lauren B. Priddy, PhD; Jeremy J. Lim, PhD; and Thomas J. Koob, PhD. Your complete research report on MDXG can be retrieved for free at:
Shares in Kalamazoo, Michigan headquartered Stryker Corp. declined 0.13%, ending yesterday's session at $140.80. A total volume of 1.46 million shares was traded, which was above their three months average volume of 1.07 million shares. The stock has gained 1.56% in the past month, 6.30% in the previous three months, and 17.52% on an YTD basis. The Company's shares are trading 2.50% above their 50-day moving average and 13.07% above their 200-day moving average. Moreover, shares of Stryker, which together with its subsidiaries, operates as a medical technology company, have an RSI of 51.63.
On June 19th, 2017, Stryker announced a definitive agreement to acquire NOVADAQ Technologies Inc. for US$11.75 per share, or US$701 million with a net purchase price of US$654 million, reflecting net cash of approximately US$47 million. NOVADAQ is a leading developer of fluorescence imaging technology that provides surgeons with visualization of blood flow in vessels and related tissue perfusion in cardiac, cardiovascular, gastrointestinal, plastic, microsurgical, and reconstructive procedures. A free report on SYK is just a click away at:
On Wednesday, Warsaw, Indiana headquartered Zimmer Biomet Holdings Inc.'s stock rose 1.02%, to close the day at $128.52. A total volume of 1.09 million shares was traded. The Company's shares have advanced 9.11% in the last one month, 5.88% in the previous three months, and 24.53% on an YTD basis. The stock is trading 6.01% and 9.85% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Zimmer Biomet, which together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, Middle-East, Africa, and Asia/Pacific, have an RSI of 73.33.
On May 30th, 2017, Zimmer Biomet announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for Q2 2017. The cash dividend of $0.24 per share will be paid on or about July 28th, 2017, to stockholders of record as of the close of business on June 23rd, 2017.
On June 21st, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $133 a share to $140 a share. Sign up for your complimentary research report on ZBH at:
Shares in San Diego, California headquartered ResMed Inc. ended the day 0.10% lower at $78.39. A total volume of 1.09 million shares was traded, which was above their three months average volume of 717,600 shares. The stock has gained 12.78% in the last one month, 9.96% in the previous three months, and 26.33% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 10.82% and 17.63%, respectively. Furthermore, shares of ResMed, which designs, develops, manufactures, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders, have an RSI of 76.84. Register for free on DailyStockTracker.com and download the latest research report on RMD at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA